Liver plays key role in how steroids cause diabetes, hypertension

Steroids called glucocorticoids are critical for treating afflictions such as asthma, arthritis and pain syndromes, but they also can trigger diabetes and hypertension. School of Medicine research now reveals why these commonly used drugs have such dangerous side effects.

The team found that a protein called peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is critical in this process and that the liver plays a key role. The findings help explain the high incidence of diabetes and hypertension in obese individuals, a group that normally produces significantly more glucocorticoids than people of average weight.

“Glucocorticoids are very effective for treating many diseases,” said first author Carlos Bernal-Mizrachi, M.D., instructor of medicine. “If we can understand the mechanisms by which these drugs cause side effects like diabetes and hypertension, we may be able to intervene and prevent these disorders in people who are taking steroids and in people who are obese.”

The study appeared online and in the August issue of the journal Nature Medicine. Bernal-Mizrachi led the study, in collaboration with Clay F. Semenkovich, M.D., professor of medicine and of cell biology and physiology and director of the Division of Endocrinology, Metabolism and Lipid Research; and Daniel P. Kelly, M.D., professor of medicine, of molecular biology and pharmacology and of pediatrics and director of the Center for Cardiovascular research.

Hypertension (persistent high blood pressure) and diabetes (chronic insulin deficiency) both are related to insulin-resistance.

PPAR-alpha is found in the liver, kidney, muscles, blood vessels and other organs. Because it is activated by fatty acids and because glucocorticoids alter fatty acid processing, Bernal-Mizrachi and his colleagues hypothesized that the two may act together to produce the disease-causing side effects.

They therefore compared mice lacking PPAR-alpha and LDLR (the receptor for low density lipoprotein, also known as “bad cholesterol”) with mice lacking only LDLR.

The team found that when given the glucocorticoid dexamethasone, mice lacking only LDLR had increased levels of insulin and fasting glucose and leptin — all signs of diabetes. The animals also became less hypoglycemic when given insulin, suggesting that they were developing insulin resistance, the precursor to diabetes. Mice lacking both LDLR and PPAR-alpha showed no signs of diabetes.

Surprisingly, dexamethasone also increased blood pressure in mice that had PPAR-alpha but not LDLR; it did not have an effect on blood pressure in mice lacking both PPAR-alpha and LDLR.

“Somehow animals missing PPAR-alpha were protected from developing diabetes and hypertension,” Semenkovich said.

The team then replaced PPAR-alpha mice livers lacking both PPAR-alpha and LDLR. The animals developed the same symptoms of diabetes and hypertension when chronically treated with dexametha-sone as mice with normal levels of PPAR-alpha throughout the body.

The team also examined human liver cells in a petri dish. When PPAR-alpha was activated and steroids were added, expression of genes related to glucose production tripled.

“The scientific community hasn’t fully appreciated the potentially important role of the liver in these conditions,” Semenkovich said. “These results strongly suggest that the liver is the key to controlling blood pressure and glucose, and our preliminary evidence with human liver cells strongly suggests that the results in mice are relevant to human disease.”

Next, Semenkovich, Bernal-Mizrachi and their colleagues plan to investigate the role of PPAR-alpha in healthy humans.

“We believe that diabetes, hypertension and many other disorders of Western civilization are related to metabolism of fatty acids, not just glucose metabolism,” Semenkovich said. “These results support that theory because PPAR-alpha is activated by fatty acids and appears to be important in the development of these problems.

Hopefully, studying this process in humans will lead to ways of preventing these potentially adverse effects of steroids and help us understand why overweight people have many of the symptoms of excess production of glucocorticoids.”

Leave a Comment

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.